relapse at low PSA values <1 ng ml −1 , the obtained detection rates of 99m Tc-labeled PSMA-SPECT/CT are lower than those reported by 68 Ga-PSMA PET/CT imaging. 1 This is in line with our experiences in early recurrent prostate cancer patients and low PSA values investigated with PSMA tracers for SPECT/CT imaging. 3 Although very useful for PSMA-radioguided surgery, 4,5 111 In-labeled PSMA I&T (or 99m Tc-labeled PSMA I&S)-based SPECT/CT detects only less than half of the metastatic lesions that are identified by previous 68 Ga-PSMA PET/CT. This is among other reasons just merely related to the different sensitivity and imaging resolution of SPECT versus PET systems. Therefore, it can be expected that also SPECT/CT with 99m Tc-labeled HYNIC-Glu-Urea-A will not be able to reliably identify recurrent disease at these very low PSA values.
Still, the authors have to be congratulated for their initial report on 99m Tc-labeled PSMA-SPECT/CT and are very much encouraged to further pursue this novel imaging technique. Tc-based bone scintigraphy, it provided not only more and more specific information for bone lesions but also revealed other prostate cancer-derived soft tissue lesions. Thus, second, as with PSMA PET/CT, PSMA SPECT/CT imaging also could provide a "one-stop-shop" imaging investigation for prostate cancer patients rendering multiple investigations (e.g., bone scintigraphy and MRI or CT of the pelvis) in most cases unnecessary. As PET/CT devices are not widely available in most countries, PSMA-based SPECT/CT imaging might here represent an interesting and less expensive imaging alternative. Finally, Su and colleagues described that in a significant number of patients (31 of fifty patients), the results of 99m Tc-labeled PSMA-SPECT/CT changed the further disease management. This finding (albeit still based on preliminary experience) underlines the impact of PSMA-targeted imaging in patients with recurrent prostate cancer.
PSMA-targeted imaging
However, there are also limitations to the presented work that have to be adequately addressed. The presented data based on a small patient cohort can only give a glimpse on the real value of 99m Tc-labeled PSMA-SPECT/CT and have to be confirmed by larger studies. Of note, especially in patients with biochemical
